1. Home
  2. WCT vs TRAW Comparison

WCT vs TRAW Comparison

Compare WCT & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WCT
  • TRAW
  • Stock Information
  • Founded
  • WCT 2012
  • TRAW 1998
  • Country
  • WCT Hong Kong
  • TRAW United States
  • Employees
  • WCT N/A
  • TRAW N/A
  • Industry
  • WCT
  • TRAW
  • Sector
  • WCT
  • TRAW
  • Exchange
  • WCT NYSE
  • TRAW NYSE
  • Market Cap
  • WCT 9.7M
  • TRAW 8.6M
  • IPO Year
  • WCT 2024
  • TRAW 2013
  • Fundamental
  • Price
  • WCT $0.21
  • TRAW $1.55
  • Analyst Decision
  • WCT
  • TRAW
  • Analyst Count
  • WCT 0
  • TRAW 0
  • Target Price
  • WCT N/A
  • TRAW N/A
  • AVG Volume (30 Days)
  • WCT 581.1K
  • TRAW 139.4K
  • Earning Date
  • WCT 05-16-2025
  • TRAW 08-14-2025
  • Dividend Yield
  • WCT N/A
  • TRAW N/A
  • EPS Growth
  • WCT N/A
  • TRAW N/A
  • EPS
  • WCT N/A
  • TRAW N/A
  • Revenue
  • WCT $2,309,218.00
  • TRAW $227,000.00
  • Revenue This Year
  • WCT N/A
  • TRAW $3.81
  • Revenue Next Year
  • WCT N/A
  • TRAW $30.43
  • P/E Ratio
  • WCT N/A
  • TRAW N/A
  • Revenue Growth
  • WCT N/A
  • TRAW 0.44
  • 52 Week Low
  • WCT $0.12
  • TRAW $0.97
  • 52 Week High
  • WCT $9.36
  • TRAW $19.44
  • Technical
  • Relative Strength Index (RSI)
  • WCT N/A
  • TRAW 50.90
  • Support Level
  • WCT N/A
  • TRAW $1.39
  • Resistance Level
  • WCT N/A
  • TRAW $1.59
  • Average True Range (ATR)
  • WCT 0.00
  • TRAW 0.09
  • MACD
  • WCT 0.00
  • TRAW -0.00
  • Stochastic Oscillator
  • WCT 0.00
  • TRAW 45.00

About WCT WELLCHANGE HOLDINGS COMPANY LIMITED

Wellchange Holdings Co Ltd is an enterprise software solution services provider. It provides software solutions, cloud-based software-as-a-service (SaaS) platforms, and white-label software design and development services.

About TRAW TRAWS PHARMA INC

Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.

Share on Social Networks: